In recent years, a new round of terrifying viruses has captured the public’s imagination. Ebola, H1N1, SARS, Zika and other pathogens strike rapidly, mutate without warning and pose a major threat to public health. We recently chatted with PaxVax CEO Nima Farzan about how we can better unite government and industry to prepare for these dangers.
Our President & CEO Sara Radcliffe provides an update on some of the other key happenings at CLSA.
Recently, the FDA announced the formation of the Patient Engagement Advisory Committee (PEAC) and requested public comments on what topics the committee should consider, which are due November 20th. FDA also published three requests for nominations to serve on the committee, including one for industry members which is due October 21st.
CLSA President & CEO Sara Radcliffe pens an op-ed in The Sacramento Bee regarding H.R. 9, federal legislation that would weaken the process that turns research into products, new companies.
CLSA Member Synergy Health hosted a facility preview event on June 30 for the newest expansion set in Petaluma, Sonoma County, CA.
On July 10, the House overwhelmingly approved the 21st Cures Act, a comprehensive legislative package to accelerate the pace of biomedical research and development in the U.S. CLSA President & CEO Sara Radcliffe comments on the passage of this landmark legislation.
Last week, CLSA Member Vertex Pharmaceuticals received FDA approval to treat Cystic Fibrosis. The approval is a shift away from prevoius CF treatments, and it addresses the underlying cause of the disease according to our partners at Biotech Primer. In their weekly email to subscribers, Biotech Primer said Vertex shifted the paradigm of treating cystic fibrosis (CF) … Continue reading A Biotech’s Treatment Changes the Game
The 12th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production from BioPlan Associates, Inc., provides global analysis of biopharma trends, based on input from 237 biomanufacturers and 164 suppliers in 28 countries. The 12th Annual Report and survey is the industry’s definitive, quantitative analysis and includes 12 years of biopharma trends analysis and … Continue reading Biosimilars, Outsourcing Impact Biopharma Manufacturing Production
CLSA members RoseRyan, Medivation, and ABD Team were recognized by the Bay Area News Group as one of the Top 100 Workplaces in the region.
The PCSK9 inhibitor buzz keeps rolling, especially since sitting before the FDA Advisory Committee earlier this month. Our friends at BiotechPrimer explain the science behind two of treatments.